Abstract:Integrin alpha(v)beta(6) is overexpressed in a variety of cancers, and its expression is often associated with poor prognosis. Therefore, there is a need to develop affinity reagents for noninvasive imaging of integrin alpha(v)beta(6) expression since it may provide early cancer diagnosis, more accurate prognosis, and better treatment planning. We recently engineered and validated highly stable cystine knot peptides that selectively bind integrin alpha(v)beta(6) with no cross-reactivity to integrins alpha(v)beta(5), alpha(5)beta(1), or alpha(v)beta(3), also known to be overexpressed in many cancers. Here, we developed a single photon emission computed tomography (SPECT) probe for imaging integrin alpha(v)beta(6) positive tumors. Cystine knot peptide, S(0)2, was first conjugated with a single amino acid chelate (SAAC) and labeled with [Tc-99m(H2O)(3)(CO)(3)](+). The resulting probe, Tc-99m-SAAC-S(0)2, was then evaluated by in vitro cell uptake studies using two alpha(v)beta(6) positive cell lines (human lung adenocarcinoma cell line HCC4006 and pancreatic cancer cell line BxPC-3) and two alpha(v)beta(6) negative cell lines (human lung adenocarcinoma cell line H838 and human embryonic kidney cell line 293T). Next, SPECT/CT and biodistribution studies were performed in nude mice bearing HCC4006 and H838 tumor xenografts to evaluate the in vivo performance of Tc-99m-SAAC-S(0)2. Significant differences in the uptake of Tc-99m-SAAC-S(0)2 were observed in alpha(v)beta(6) positive vs negative cells (P < 0.05). Biodistribution and small animal SPECT/CT studies revealed that Tc-99m-SAAC-S(0)2 accumulated to moderate levels in antigen positive tumors (similar to 2% ID/g at 1 and 6 h postinjection, n = 3 or 4/group). Moreover, the probe demonstrated tumor-to-background tissue ratios of 6.81 +/- 2.32 (tumor-to-muscle) and 1.63 +/- 0.18 (tumor-to-blood) at 6 h postinjection in alpha(v)beta(6) positive tumor xenografts. Co-incubation of the probe with excess amount of unlabeled S(0)2 as a blocking agent demonstrated significantly reduced tumor uptake, which is consistent with specific binding to the target. Renal filtration was the main route of clearance. In conclusion, knottin peptides are excellent scaffolds for which to develop highly stable imaging probes for a variety of oncological targets. Tc-99m-SAAC-S(0)2 demonstrates promise for use as a SPECT agent to image integrin alpha(v)beta(6) expression in living systems.

68Ga-Trivehexin PET/CT in Metastatic Non-Small Cell Lung Cancer to the Brain

Potential Efficacy of 68 Ga-Trivehexin PET/CT and Immunohistochemical Validation of αvβ6 Integrin Expression in Patients With Head and Neck Squamous Cell Carcinoma and Pancreatic Ductal Adenocarcinoma

Integrin Α6-Targeted Positron Emission Tomography Imaging of Colorectal Cancer

"Cancer Integrin" αvβ6 Imaging With 68Ga-Trivehexin PET/CT in Assessment of Ovarian Carcinoma

"Cancer Integrin" α v β 6 Imaging With 68 Ga-Trivehexin PET/CT in Assessment of Ovarian Carcinoma

Integrin Imaging with 99Mtc-3Prgd2 SPECT/CT Shows High Specificity in the Diagnosis of Lymph Node Metastasis from Non-Small Cell Lung Cancer.

99Mtc-3P-rgd2 Micro-Single-Photon Emission Computed Tomography/Computed Tomography Provides a Rational Basis for Integrin Αvβ3-Targeted Therapy

Inter-heterogeneity and Intra-Heterogeneity of Αvβ3 in Non-Small Cell Lung Cancer and Small Cell Lung Cancer Patients As Revealed by 68Ga-Rgd2 PET Imaging.

Radiolabeled Cyclic RGD Peptides As Radiotracers for Tumor Imaging.

99Mtc-3Prgd2 for Integrin Receptor Imaging of Lung Cancer: A Multicenter Study

Advancing Cancer Theranostics Through Integrin αVβ3-Targeted Peptidomimetic IAC: From Bench to Bedside

Development and Preclinical Evaluation of a Cyclic PET Tracer Targeting Integrin-Α6 on Colorectal Cancer Models

A Ga-68 Labeled Peptide for Imaging of {alpha}v{beta}6 Positive Tumor

99Mtc-Hisodgr As a Potential SPECT Probe for Orthotopic Glioma Detection Via Targeting of Integrin Α5β1

Clinical Translation of a 68Ga-Labeled Integrin Αvβ6–targeting Cyclic Radiotracer for PET Imaging of Pancreatic Cancer

99mTc-labeled cystine knot peptide targeting integrin αvβ6 for tumor SPECT imaging.

An Integrin Alpha 6-Targeted Radiotracer with Improved Receptor Binding Affinity and Tumor Uptake

Integrin Αvβ6–targeted SPECT Imaging for Pancreatic Cancer Detection

First-in-human Pilot Study of an Integrin Α6-Targeted Radiotracer for SPECT Imaging of Breast Cancer

Biodistribution in Healthy KM Mice and Micro PET/CT Imaging in U87MG Tumor-Bearing Nude Mice of a New 18F-Labeled Cyclic RGD Dimer

68 Ga-labeled Cyclic RGD Dimers with Gly 3 and PEG 4 Linkers: Promising Agents for Tumor Integrin Α V Β 3 PET Imaging